Volume 6, Issue 4, December 2018, Page: 54-59
Influence of Estrogen, Bevacizumab and Other Factors on VEGF Expression in SKBR-3 Breast Cancer Cells
Zinan Wang, Department of Breast, Yan’an Hospital of Kunming City, Kunming, China
Dezhong Zhao, Department of Breast, Yan’an Hospital of Kunming City, Kunming, China
Ruobing Liu, Department of Breast, Yan’an Hospital of Kunming City, Kunming, China
Bin Zheng, Department of Breast, Yan’an Hospital of Kunming City, Kunming, China
Received: Nov. 14, 2018;       Accepted: Dec. 5, 2018;       Published: Jan. 15, 2019
DOI: 10.11648/j.jctr.20180604.11      View  323      Downloads  59
Abstract
OBJECTIVE: To investigate expression of VEGF of SKBR-3 breast cancer cells in different estrogen and to investigate the expression of VEGF after Bevacizumab, Trastuzumab, Taxol and Insulin-like growth factor 1 receptor (IGF-1R)antibodies treatment in different estrogen. METHODS: RT-PCR was used to detect the expression of VEGF in SKBR-3 breast cancer cells under different concentrations of estrogen and VEGF monoclonal antibody, HER-2 monoclonal antibody, paclitaxel and IGF-1R antibody. At the same time, ELISA was used to detect the concentration of VEGF protein in the culture supernatant. RESULTS: The expression of VEGF in no estrogen group was 1.0618±0.0085 (VEGF/GAPDH); the expression of VEGF in low concentration group (50pg/L) was 1.0047±0.0061, the difference was statistically significant compared with the no estrogen group (P=0.002); the expression of VEGF in high concentration group (0.2 μg/mL) was 1.0868±0.0135, the difference was statistically significant compared with the no estrogen group (P<0.001). The expression of VEGF were 1.0496±0.0288 and 1.0618±0.0085 in Taxol group and contral Group (F=0.058), the expression of VEGF were 1.0884±0.0036, 1.0618 ±0.0085 in antibody of IGF-1R group and contral group (F=0.073), the expression of VEGF were 0.9887±0.0037, 1.0618±0.0085 in Trastuzumab group and contral group (F=0.075). The expression of VEGF in the paclitaxel group and the control group were 1.0496±0.0288 and 1.0618±0.0085(F=0.058);The expression of VEGF in IGF-1R group and control group were 1.0884±0.0036 and 1.0618±0.0085(F=0.073);The expression of VEGF in the trastuzumab group and the control group were 0.9887±0.0037 and 1.0618±0.0085(F=0.075); There was no significant change in the expression of VEGF in the paclitaxel group, the IGF-1R group antibody and the trastuzumab group with estrogen. The expression of VEGF in the bevacizumab group and the control group were 1.0057±0.0043 and 1.0618±0.0085( F=0.132, P=0.04), and There is no synergistic effect of estrogen and VEGF monoclonal antibody on the expression of VEGF. Conclusion: The influence of different estrogen on VEGF-expression in SKBR-3 breast cancer cells is remarkable. Taxol, antibody of IGF-1R and Trastuzumab do not change the expression of VEGF in SKBR-3 breast cancer cells, and this has no synergistic effect with estrogen.. Bevacizumab increases the expression of VEGF, and this also has no synergistic effect with estrogen.
Keywords
SKBR-3 Breast Cancer Cell Line, Estrogen, Bevacizumab, Vascular Endothelial Growth Factor, IGF-1R Antibody, Trastuzumab
To cite this article
Zinan Wang, Dezhong Zhao, Ruobing Liu, Bin Zheng, Influence of Estrogen, Bevacizumab and Other Factors on VEGF Expression in SKBR-3 Breast Cancer Cells, Journal of Cancer Treatment and Research. Vol. 6, No. 4, 2018, pp. 54-59. doi: 10.11648/j.jctr.20180604.11
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Folkman J. Folkman, J. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 3, 65-71 [J]. Seminars in Cancer Biology, 1992, 3(2): 65-71.
[2]
Zhu Liangjie. Correlation between vascular endothelial growth factor levels and lung cancer and breast cancer [J]. China Minkang Medicine, 2017, 29 (20): 36-37.
[3]
Bausero P, Benmahdi M, Mazucatelli J, et al. Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen, and hypoxia. [J]. Am J Physiol Heart Circ Physiol, 2000, 279(5): H2033.
[4]
Li Hua, Sun Hong. Effects of estrogen and progesterone on the expression of VEGF mRNA in ovarian cancer cells [J]. Chinese Journal of Oncology, 2004, 26(5): 11-14.
[5]
Sengupta K, Banerjee S, Saxena N, et al. Estradiol-induced vascular endothelial growth factor-A expression in breast tumor cells is biphasic and regulated by estrogen receptor-alpha dependent pathway [J]. International Journal of Oncology, 2003, 22(3): 609-614.
[6]
Sengupta K, Banerjee S, Saxena N K, et al. Differential expression of VEGF-A mRNA by 17beta-estradiol in breast tumor cells lacking classical ER-alpha may be mediated through a variant form of ER-alpha. [J]. Molecular & Cellular Biochemistry, 2004, 262(1-2): 215-224.
[7]
Buteaulozano H, Ancelin M, Lardeux B, et al. Transcriptional Regulation of Vascular Endothelial Growth Factor by Estradiol and Tamoxifen in Breast Cancer Cells A Complex Interplay between Estrogen Receptors α and β [J]. Cancer Research, 2002, 62(17): 4977.
[8]
Johns A, Freay AD, Fraser W, et al. Disruption of estrogen receptor gene prevents 17 beta estradiol-induced angiogenesis in transgenic mice [J]. Endocrinology, 1996, 137(10): 4511-4513.
[9]
Xiong Zhihong, Ding Lihua, Yang Shuxing, et al. Construction of reporter gene containing VEGF promoter and effects of estrogen receptor on its activity [J]. Biotechnology Communication, 2007, 18(6): 915-917.
[10]
Klos K S, Wyszomierski S L, Sun M, et al. ErbB2 Increases Vascular Endothelial Growth Factor Protein Synthesis via Activation of Mammalian Target of Rapamycin/p70S6K Leading to Increased Angiogenesis and Spontaneous Metastasis of Human Breast Cancer Cells [J]. Cancer Research, 2006, 66(4): 2028-2037.
[11]
Finkenzeller G, Weindel K, Zimmermann W, et al. Activated Neu/ErbB-2 induces expression of the vascular endothelial growth factor gene by functional activation of the transcription factor Sp 1 [J]. Angiogenesis, 2004, 7(1): 59-68.
[12]
Read L D, Jr K D, Slamon D J, et al. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines [J]. Cancer Research, 1990, 50(13): 3947-3951.
[13]
Wang Junfang. The application effect of paclitaxel in the chemotherapy of breast cancer [J]. Strait Pharmaceutical, 2018, 30(08): 153-154.
[14]
Volk L D, Flister M J, Bivens C M, et al. Nab-paclitaxel Efficacy in the Orthotopic Model of Human Breast Cancer Is Significantly Enhanced By Concurrent Anti–Vascular Endothelial Growth Factor A Therapy [J]. Neoplasia, 2008, 10(6): 613-623.
[15]
Wang Qing, Zhai Fang, Wang Ning, et al. Correlation between ER and HER-2 expression status in late breast cancer and recent effective rate of TE regimen chemotherapy [J]. Journal of Medical Research, 2010, 39(4): 22-25.
[16]
Reiss K, D'Ambrosio C, Tu X, et al. Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect. [J]. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 1998, 4(11): 2647-2655.
[17]
Beckert S, Farrahi F, Perveen Ghani Q, et al. IGF-I-induced VEGF expression in HUVEC involves phosphorylation and inhibition of poly (ADP-ribose) polymerase. [J]. Biochemical & Biophysical Research Communications, 2006, 341(1): 67-72.
[18]
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792.
[19]
Zhang Honghuan. Therapeutic effect of trastuzumab in the treatment of 40 cases of Her-2 positive breast cancer [J]. Chinese and foreign women's health research, 2018 (18): 112 + 115.
[20]
Tsai PW, Shiah SG, Lin MT, Wu CW, Kuo ML. Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway. [J]. The Journal of Biological Chemistry, 2003, 278(8): 5750-5759.
[21]
Robert N J, Dieras V, Glaspy J A, et al. RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer [J]. Journal of Clinical Oncology, 2011, 29(10): 1252-1260.
[22]
Chen Lijia. Clinical efficacy of bevacizumab combined with TP regimen in the treatment of advanced HER2-negative breast cancer and its effect on related cytokine levels [J]. Labeled Immunoassays and Clinical Medicine, 2018, 25(07): 963-965 +986.
Browse journals by subject